美国银行将BridgeBio Pharma的价格目标提升至45美元, Bank of America raises BridgeBio Pharma's price target to $45, keeping a "Moderate Buy" average rating.

一些分析家调整了BridgeBio Pharma(BBIO)的价格目标,美国银行将其目标提高到45美元,并保持了买入评级。 Several analysts have adjusted their price targets for BridgeBio Pharma (BBIO), with Bank of America raising its target to $45 and maintaining a buy rating. 尽管有些降级,但平均评级仍然是“机动购买”,协商一致目标是48.43美元。 Despite some downgrades, the average rating remains a "Moderate Buy" with a consensus target of $48.43. HC Wainwright最近将其目标提高到49美元,而主要内部人士则出售了大量股票。 HC Wainwright recently raised its target to $49, while key insiders have sold significant shares. 该公司的市场上限为52亿美元,重点关注遗传疾病和癌症。 The company has a market cap of $5.2 billion and focuses on genetic diseases and cancers.